Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients

Study Summary

This multi-year cohort study will assess the real-world safety and effectiveness of 1L treatment with cemiplimab in combination with platinum-doublet chemotherapy across advanced NSCLC patient subgroups defined by age, sex, race, and ethnicity. Patients will be retrospectively identified from at least two US electronic health record (EHR)-based databases.

Conditions

Advanced Non-small Cell Lung Cancer

Interventions / Drugs

REGN2810 Platinum-doublet chemotherapy

View on ClinicalTrials.gov ↗

Sponsor

REGN

Regeneron Pharmaceuticals

Antibody Therapeutics

F34/100

Study Details

Enrollment1000 participants

Primary Completion—

Lead SponsorRegeneron Pharmaceuticals

Data Retrieved2026-04-11 02:55:54.866078+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.